Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle
Open Access

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study

Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef and Irene E. van der Horst-Bruinsma
The Journal of Rheumatology November 2018, jrheum.180312; DOI: https://doi.org/10.3899/jrheum.180312
Rianne E. van Bentum
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sjoerd C. Heslinga
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael T. Nurmohamed
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas H. Gerards
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ed N. Griep
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte B.J.M. Koehorst
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc R. Kok
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna M. Schilder
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marijn Verhoef
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene E. van der Horst-Bruinsma
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
Next
Loading

Abstract

Objective Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS). Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS. To date, the effect of GOL on the incidence of AAU in AS is unknown. The objective was to study the AAU occurrence rate in patients with AS during GOL treatment and secondarily, the efficacy of GOL in daily clinical practice.

Methods The study was a multicenter prospective study in a real-world setting in patients with AS who were treated with GOL for 12 months. The occurrence of AAU was assessed in the year before the initial TNFi treatment and during GOL treatment and calculated for the period at risk for a new AAU. Measures for disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)] and treatment response [Assessment of Spondyloarthritis international Society (ASAS20 score)] were collected.

Results In total, 93 patients (65% male, 55% TNFi-naive, 27% history of AAU) were included, with a median disease duration of 7 years and ASDAS score of 3.1. During GOL treatment, the AAU occurrence rate was reduced from 11.1 to 2.2 per 100 patient-years (rate-ratio 0.20, 95% CI 0.04–0.91). After 3 months of treatment, 41% of the patients experienced a clinically important improvement of the ASDAS score (p < 0.001) and 36% an ASDAS20 response (p < 0.001). At month 12, 49% had achieved an ASAS20 response (p < 0.001).

Conclusion In AS, the AAU occurrence rate and disease activity decreased significantly during GOL treatment. Therefore, GOL can be considered a good choice in patients with AS who need a TNFi, especially in cases of recurrent AAU. (EudraCT number: 2012-002458-21)

Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 49, Issue 5
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef, Irene E. van der Horst-Bruinsma
The Journal of Rheumatology Nov 2018, jrheum.180312; DOI: 10.3899/jrheum.180312

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef, Irene E. van der Horst-Bruinsma
The Journal of Rheumatology Nov 2018, jrheum.180312; DOI: 10.3899/jrheum.180312
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • The Association of Illness-related Uncertainty With Mental Health in Systemic Autoimmune Rheumatic Diseases
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire